In addition, NRP-1 and HER-2/neu expression have a negative predictive value for overall survival and progression-free survival, respectively, in this population of squamous cell carcinoma of head and neck treated with sorafenib and may predict resistance to this agent, however, further studies are needed. This evidence concerns the gene ERBB2 and squamous cell carcinoma.